The European Bronchiectasis Registry is supported by the European Union Innovative Medicines Initiative under the "New Drugs for Bad Bugs" programme, to help facilitate the development of new antibiotics against Gram-negative infections

EMBARC work closely with the European Lung Foundation to promote patient priorities and improve patient education and resources.

The largest bronchiectasis biobanking study is underway and will gather in depth data on cilia, inflammatory markers and many more clinical measures linked to the registry.

The largest prospective registry of bronchiectasis globally with an initial report of 16,963 patients from 28 countries has now been published. It describes the frequency of different aetiologies, microbiology, treatments, and disease burden in terms of lung function, exacerbation frequency, hospitalisations and disease severity.

In most cases, the cause of bronchiectasis is unknown. Where aetiology has been confirmed, postinfective bronchiectasis is the most common.

Bronchiectasis severity as determined by the Bronchiectasis Severity Index (BSI) also shows geographical variation.

Microbiology data shows Pseudomonas aeruginosa and Haemophilus influenzae outnumber all other pathogens isolated from patient samples.

EMBARC works with the European Respiratory Society and the national societies and networks around the world to promote co-operation, data sharing and clinical research in bronchiectasis